Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
D6GEEvJnNcjc2QA1
